Cardiol 2008; 51:1357. 31. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008; 359:1009. 32. Sweeney MO, Sherfesee L, DeGroot PJ, et al. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm 2010; 7:353. 33. Sood N, Ruwald AC, Solomon S, et al. Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT. Eur Heart J 2014; 35:106. 34. Powell BD, Saxon LA, Boehmer JP, et al. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol 2013; 62:1674. 35. van Rees JB, Borleffs CJ, de Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011; 57:556. 36. Schaumann A, von zur M hlen F, Herse B, et al. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients. Circulation 1998; 97:66. 37. Trappe HJ, Klein H, Kielblock B. Role of antitachycardia pacing in patients with third generation cardioverter defibrillators. Pacing Clin Electrophysiol 1994; 17:506. 38. Saksena S, Chandran P, Shah Y, et al. Comparative efficacy of transvenous cardioversion and pacing in patients with sustained ventricular tachycardia: a prospective, randomized, https://www.uptodate.com/contents/implantable-cardioverter-defibrillators-optimal-programming/print 23/29 7/6/23, 3:08 PM Implantable cardioverter-defibrillators: Optimal programming - UpToDate crossover study. Circulation 1985; 72:153. 39. Bardy GH, Poole JE, Kudenchuk PJ, et al. A prospective randomized repeat-crossover comparison of antitachycardia pacing with low-energy cardioversion. Circulation 1993; 87:1889. 40. Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoracotomy: an international multicenter study. PCD Investigator Group. J Am Coll Cardiol 1994; 23:1521. 41. Sullivan RM, Russo AM, Berg KC, et al. Arrhythmia rate distribution and tachyarrhythmia therapy in an ICD population: results from the INTRINSIC RV trial. Heart Rhythm 2012; 9:351. 42. Wilkoff BL, Ousdigian KT, Sterns LD, et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 2006; 48:330. 43. Sweeney MO, Wathen MS, Volosin K, et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation 2005; 111:2898. 44. Gilliam FR, Hayes DL, Boehmer JP, et al. Real world evaluation of dual-zone ICD and CRT-D programming compared to single-zone programming: the ALTITUDE REDUCES study. J Cardiovasc Electrophysiol 2011; 22:1023. 45. Fischer A, Ousdigian KT, Johnson JW, et al. The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients. Heart Rhythm 2012; 9:24. 46. Gonz lez-Enr quez S, Rodr guez-Entem F, Exp sito V, et al. Single-chamber ICD, single-zone therapy in primary and secondary prevention patients: the simpler the better? J Interv Card Electrophysiol 2012; 35:343. 47. Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004; 110:2591. 48. Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001; 104:796. https://www.uptodate.com/contents/implantable-cardioverter-defibrillators-optimal-programming/print 24/29 7/6/23, 3:08 PM Implantable cardioverter-defibrillators: Optimal programming - UpToDate 49. Saeed M, Neason CG, Razavi M, et al. Programming antitachycardia pacing for primary prevention in patients with implantable cardioverter defibrillators: results from the PROVE trial. J Cardiovasc Electrophysiol 2010; 21:1349. 50. Sivagangabalan G, Eshoo S, Eipper VE, et al. Discriminatory therapy for very fast ventricular tachycardia in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2008; 31:1095. 51. Schoels W, Steinhaus D, Johnson WB, et al. Optimizing implantable cardioverter-defibrillator treatment of rapid ventricular tachycardia: antitachycardia pacing therapy during charging. Heart Rhythm 2007; 4:879. 52. Gasparini M, Anselme F, Clementy J, et al. BIVentricular versus right ventricular antitachycardia pacing to terminate ventricular tachyarrhythmias in patients receiving cardiac resynchronization therapy: the ADVANCE CRT-D Trial. Am Heart J 2010; 159:1116. 53. Ruwald AC, Schuger C, Moss AJ, et al. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circ Arrhythm Electrophysiol 2014; 7:785. 54. Nasir N Jr, Pacifico A, Doyle TK, et al. Spontaneous ventricular tachycardia treated by antitachycardia pacing. Cadence Investigators. Am J Cardiol 1997; 79:820. 55. Pinski SL, Fahy GJ. The proarrhythmic potential of implantable cardioverter-defibrillators. Circulation 1995; 92:1651. 56. Martins RP, Blangy H, Muresan L, et al. Safety and efficacy of programming a high number of antitachycardia pacing attempts for fast ventricular tachycardia: a prospective study. Europace 2012; 14:1457. 57. Anguera I, Dallaglio P, Sabat X, et al. The benefit of a second burst antitachycardia sequence for fast ventricular tachycardia in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2014; 37:486. 58. Santini M, Lunati M, Defaye P, et al. Prospective multicenter randomized trial of fast ventricular tachycardia termination by prolonged versus conventional anti-tachyarrhythmia burst pacing in implantable cardioverter-defibrillator patients-Atp DeliVery for pAiNless ICD thErapy (ADVANCE-D) Trial results. J Interv Card Electrophysiol 2010; 27:127. 59. Gulizia MM, Piraino L, Scherillo M, et al. A randomized study to compare ramp versus burst antitachycardia pacing therapies to treat fast ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators: the PITAGORA ICD trial. Circ Arrhythm Electrophysiol 2009; 2:146. https://www.uptodate.com/contents/implantable-cardioverter-defibrillators-optimal-programming/print 25/29 7/6/23, 3:08 PM Implantable cardioverter-defibrillators: Optimal programming - UpToDate 60. Strik M, Ramirez FD, Welte N, et al. Progressive implantable cardioverter-defibrillator therapies for ventricular tachycardia: The efficacy and safety of multiple bursts, ramps, and low-energy shocks. Heart Rhythm 2020; 17:2072. 61. Castelnuovo E, Stein K, Pitt M, et al. The effectiveness and cost-effectiveness of dual- chamber pacemakers compared with single-chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome: systematic review and economic evaluation. Health Technol Assess 2005; 9:iii, xi. 62. Toff WD, Camm AJ, Skehan JD, United Kingdom Pacing and Cardiovascular Events Trial Investigators. Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. N Engl J Med 2005; 353:145. 63. Francia P, Adduci C, Palano F, et al. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy. J Cardiovasc Electrophysiol 2015; 26:893. 64. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable- cardioverter defibrillator. Circulation 2013; 128:944. 65. Gold MR, Theuns DA, Knight BP, et al. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol 2012; 23:359. 66. Gold MR, Weiss R, Theuns DA, et al. Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm 2014; 11:1352. 67. Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. Subcutaneous or Transvenous Defibrillator Therapy. N Engl J Med 2020; 383:526. 68. Mandrola J, Enache B, Redberg RF. Subcutaneous or Transvenous Defibrillator Therapy. N Engl J Med 2021; 384:676. Topic 113776 Version 15.0 https://www.uptodate.com/contents/implantable-cardioverter-defibrillators-optimal-programming/print 26/29 7/6/23, 3:08 PM Implantable cardioverter-defibrillators: Optimal programming - UpToDate GRAPHICS Tachycardia detection evidence Short detection controls Prolonged detection intervention Participants (n) Study Findings PREPARE 1391 12 of 16 (58%) 30 of 40 beats Reduction in Nonrandomized beats inappropriate shocks (SVT), Primary prevention 18 of 24 (42%) beats avoidable shocks (VT), and "morbidity index" RELEVANT 324 Nonrandomized 12 of 16 beats 30 of 40 beats Reduction in inappropriate shocks (SVT), Primary prevention avoidable shocks (VT), and HF hospitalizations MADIT-RIT 1500 Randomized 2.5 seconds (170 to 199 bpm) 60 seconds (170 to 199 bpm) Reduction in first inappropriate Primary prevention therapy, first 1 second ( 200 bpm) 12 seconds (200 appropriate therapy, to 249 bpm) 2.5 seconds ( 250 bpm) appropriate ATP, and inappropriate ATP; improved survival ADVANCE-III 1902 Randomized 18 of 24 beats 30 of 40 beats Reduction in overall therapies, inappropriate Primary and secondary shocks, and all- prevention cause hospitalizations PROVIDE 1670 Randomized 12 beats 25 beats (180 to Reduction in all- 214 bpm) cause shock rate; improved survival Primary prevention 18 beats (214 to 250 bpm) 12 beats (>250 bpm) https://www.uptodate.com/contents/implantable-cardioverter-defibrillators-optimal-programming/print 27/29 7/6/23, 3:08 PM Implantable cardioverter-defibrillators: Optimal programming - UpToDate SVT: supraventricular tachycardia; VT: ventricular tachycardia; HF: heart failure; bpm: beats per minute; ATP: antitachycardia pacing. Reproduced from: Wilko BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-de brillator programming and testing. Heart Rhythm 2016; 13:e50. Table used with the permission of Elsevier Inc. All rights reserved. Graphic 115226 Version 1.0 https://www.uptodate.com/contents/implantable-cardioverter-defibrillators-optimal-programming/print 28/29 7/6/23, 3:08 PM Implantable cardioverter-defibrillators: Optimal programming - UpToDate Contributor Disclosures Martin K Stiles, MB ChB, PhD, FRACP, FHRS Consultant/Advisory Boards: Ceryx Medical [Novel pacemaker device]. Speaker's Bureau: Medtronic [AF ablation]. All of the relevant financial relationships listed have been mitigated. Jonathan Piccini, MD, MHS, FACC, FAHA, FHRS Grant/Research/Clinical Trial Support: Abbott [Atrial fibrillation, catheter ablation]; AHA [Atrial fibrillation, cardiovascular disease]; Bayer [Atrial fibrillation]; Boston Scientific [Cardiac mapping, pacemaker/ICD, atrial fibrillation care]; iRhythm [Atrial fibrillation]; NIA [Atrial fibrillation]; Philips [Lead management]. Consultant/Advisory Boards: Abbott [Atrial fibrillation, catheter ablation]; Abbvie [Atrial fibrillation]; Bayer [Atrial fibrillation]; Boston Scientific [Cardiac mapping, atrial fibrillation, pacemaker/ICD]; ElectroPhysiology Frontiers [Atrial fibrillation, catheter ablation]; Element Science [DSMB]; Medtronic [Atrial fibrillation, pacemaker/ICDs]; Milestone [Supraventricular tachycardia]; Pacira [Atrial fibrillation]; Philips [Lead extraction]; ReCor [Cardiac arrhythmias]; Sanofi [Atrial fibrillation]. All of the relevant financial relationships listed have been mitigated. Nisha Parikh, MD, MPH No relevant financial relationship(s) with ineligible companies to disclose. Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence. Conflict of interest policy https://www.uptodate.com/contents/implantable-cardioverter-defibrillators-optimal-programming/print 29/29